Remote Ischemic Postconditioning in Septic Shock

Study acronym: RIPOST-sepsis
StatusNot Yet Recruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 8 months later Jul 2028 → Apr 2029
See other at-risk trials from Hospices Civils de Lyon

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Jul 2028 to Apr 2029 Show 4 more changesShow less
    • Start date: Apr 2026 to Jan 2027
    • Eligibility criteria expanded, about 10 words
    • Secondary endpoints: details revised at 1 of 5 entries
    • Site details revised at 1 of 23 sites
  2. Primary and study completion dates: Jun 2028 to Jul 2028v2 Show 4 more changesShow less
    • Start date: Mar 2026 to Apr 2026
    • Interventions: Control group (Other), Remote ischemic conditioning (Other) to No intervention (Other), Remote ischemic conditioning (Other)
    • Secondary endpoints: 3 to 5
    • Site contacts updated at 1 of 23 sites
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Septic shock is a leading cause of death worldwide despite intensive research efforts. Only a few interventions have been proven to be effective in improving patient-centered outcomes. Recent clinical trials have reported the safety and efficacy of remote ischemic postconditioning (RIPOST) in a variety of pathologies, including myocardial infarction, cardiac surgery, and stroke. While RIPOST was mainly tested in pathologies with low mortality rates, several follow-up studies of large randomized clinical trials in acute myocardial infarction and in patients undergoing coronary artery bypass surgery have reported significant decreases (\> 50%) in long-term mortality. Experimental studies and proof-of-concept clinical trials have also suggested the potential benefits of RIPOST on mortality in sepsis and septic shock. The present protocol aims to test whether this non-invasive, widely available, inexpensive, and innovative intervention can improve survival in septic shock.
Trial Details
NCT Number NCT07273942
Lead Sponsor Hospices Civils de Lyon
Conditions
(from sponsor)		 Adult Patients With Septic Shock Admitted in Intensive Care Unit
Related terms Shock, Septic
Enrollment 720 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov